Skip to Content



Leukemia Insights - Spring 2012

  1. Thorson J, Sievers E, Ahlert J, et al. Understanding and exploiting nature’s chemical arsenal: the past, present and future of calicheamicin research. Cur Pharm Des 6: 1841-79, 2000.
  2. Ricart A. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res; 17(20) 6417-6427, 2011.
  3. Advani A, Coiffier B, Czuczman M, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol 28, 2085-93, 2010.
  4. Di Joseph J, Dougher M, Kalyandrug L, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Can Res 12: 242-249, 2006.
  5. Kantarjian H, Jabbour E, Jorgensen J, et al. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, shows significant antileukemic activity in patients with refractory-relapsed acute lymphocytic leukemia. Submitted, 2011.
  6. Schultz K, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children’s Oncology Group study. Journ of Clin Onc 27 (31): 5175-5181, 2009.
  7. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. JCO 29:2493-8, 2011.
  8. Herrera L et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 14:853-858, 2000 and Herrera L et al. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 17:334-338, 2003.
  9. Vallera DA et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res. 11:3879-3888, 2005.
  10. Ravandi F et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-7, 2010.
  11. Gandhi V et al. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol 26(7):1098-1105, 2008.
  12. Tiwari KN et al. Synthesis of 4’-thio-beta-D-arabinofuranosylcytosine (4’-thio-ara-C) and comparison of its anticancer activity with that of ara-C. Nucleosides, Nucleotides, Nucleic Acids 19:329-340, 2000 and Parker WB et al. Proc Am Assoc Ca Res 40:297, 1999.
  13. Bercovich D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome. Lancet 372:1484-92, 2008 and Mullighan CG et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 106:9414-8, 2009.

© 2015 The University of Texas MD Anderson Cancer Center